National Health and Family Planning Commission, P.R.China   Report issue

Government Phase 4
Founded: Beijing China (2013)

Organization Overview

First Clinical Trial
2014
NCT02327663
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

National Health and Family Planning Commission, P.R.China

Active Ingredients

Drugs in Phase 4 Trials (3)

emtricitabine (emtriva) (5 trials)

tenofovir (viread) (1 trial)

xuebijing (1 trial)

Drugs in Other Trials (1)

alteplase (Activase) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Liver Cirrhosis (Phase 4)

Sepsis (Phase 4)

Toxemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 4